TWiV 994: Clinical update with Dr. Daniel Griffin

In his weekly clinical update, Dr. Griffin discusses the detection of circulating vaccine-derived poliovirus type 2 in Burundi and the Democratic Republic of the Congo, the novel oral polio vaccine type 2 story, prior COVID-19 infection associated with increased risk of newly diagnosed erectile dysfunction, adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection, correlates of protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals exposed to SARS-CoV-2 in households in Israel, effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths in people with COVID-19, projected COVID-19 mortality reduction from Paxlovid rollout, and SARS-CoV-2 mRNA vaccines decouple anti-viral immunity from humoral autoimmunity. Subscribe (free): Apple Podcasts , Google Podcasts , RSS , email Become a patron of TWiV! Links for this episode cVDPV2 detections in Burundi and the DRC (PGEI) Novel oral polio vaccine type 2 story (The Lancet) Prior COVID-19 infection associated with risk of diagnosed erectile dysfunction (IJIR) Adverse maternal, fetal, and newborn outcomes among pregnant women with SARS-CoV-2 infection (BMJ) Protection against COVID-19 infection and intensity of symptomatic disease in vaccinated individuals (The Lancet) Effectiveness of Nirmatrelvir–Ritonavir in preventing hospital admissions and deaths (The Lancet) Projected COVID-19 mortality reduction from Paxlovid rollout (JAMA) SARS-CoV-2 mRNA vaccines decouple anti-viral immunity (Nature) Contribute to our ASTMH fundraiser at PWB Dr. Griffin's treatment guide ( pdf ) Letters read on TWiV 994 Don't crush Paxlovid ( pdf ) Timestamps by Jolene . Thanks! Intro music is by Ronald Jenkees Send your questions for Dr. Griffin to [email protected]